The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALVO | -54.52% | N/A | N/A | -44% |
| S&P | +13.19% | +87.83% | +13.42% | +90% |
Alvotech operates as a global biopharmaceutical company, which engages in developing and manufacturing biosimilar medicines. It operates through the following geographical segments: North America, Europe, Asia, and Other. The company was founded by Róbert Wessman on August 23, 2021 and is headquartered in Luxembourg.
The biosimilar drug company's shares rebounded a day after it announced that the FDA had dealt it setback.
The Icelandic biotech company has a deal to expand the reach of its Humira biosimilar in Eastern Europe.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $113.74M | 10.6% |
| Gross Profit | $78.74M | 24.8% |
| Gross Margin | 69.22% | 7.9% |
| Market Cap | $2.47B | -31.1% |
| Market Cap / Employee | $2.40M | 0.0% |
| Employees | 1K | 0.6% |
| Net Income | -$5.25M | 53.9% |
| EBITDA | $11.48M | -45.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $42.85M | -63.8% |
| Accounts Receivable | $121.35M | -16.6% |
| Inventory | 207.7 | 66.2% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.23B | 6.9% |
| Short Term Debt | $56.02M | 65.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 5.26% | 45.5% |
| Return On Invested Capital | -170.25% | 34.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$74.50M | 12.8% |
| Operating Free Cash Flow | -$55.58M | 22.4% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Earnings | 28.68 | 43.45 | 35.56 | - | |
| Price to Book | -11.60 | -7.07 | -9.11 | -14.26 | 159.88% |
| Price to Sales | 8.58 | 4.98 | 4.91 | 4.33 | -55.66% |
| Price to Tangible Book Value | -10.60 | -6.56 | -8.22 | -10.26 | 96.81% |
| Enterprise Value to EBITDA | 263.30 | 218.45 | 144.09 | 323.35 | 46.18% |
| Total Debt | $1.19B | $1.23B | $1.27B | $1.28B | 8.61% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
